Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro

被引：6

作者：

Brownlow, N. ^{[1
]}

Vaid, M. ^{[1
]}

Dibb, N. J. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England

来源：

LEUKEMIA | 2008年 / 22卷 / 07期

基金：

英国生物技术与生命科学研究理事会;

关键词：

D O I：

10.1038/sj.leu.2405085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：1452 / 1453

页数：3

相关论文

共 8 条

[1]

BROWNLOW N, 2007, LEUKEMIA

[2]

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 [J].

Clark, JJ ;

Cools, J ;

Curley, DP ;

Yu, JC ;

Lokker, NA ;

Giese, NA ;

Gilliland, DG .

BLOOD, 2004, 104 (09) :2867-2872

[3]

Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis [J].

Condeelis, J ;

Pollard, JW .

CELL, 2006, 124 (02) :263-266

[4]

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics [J].

DeAngelo, Daniel J. ;

Stone, Richard M. ;

Heaney, Mark L. ;

Nimer, Stephen D. ;

Paquette, Ronald L. ;

Klisovic, Rebecca B. ;

Caligiuri, Michael A. ;

Cooper, Michael R. ;

Lecerf, Jean-Michel ;

Karol, Michael D. ;

Sheng, Shihong ;

Holford, Nick ;

T Curtin, Peter ;

Druker, Brian J. ;

Heinrich, Michael C. .

BLOOD, 2006, 108 (12) :3674-3681

[5]

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) [J].

Kelly, LM ;

Yu, JC ;

Boulton, CL ;

Apatira, M ;

Li, J ;

Sullivan, CM ;

Williams, I ;

Amaral, SM ;

Curley, DP ;

Duclos, N ;

Neuberg, D ;

Scarborough, RM ;

Pandey, A ;

Hollenbach, S ;

Abe, K ;

Lokker, NA ;

Gilliland, DG ;

Giese, NA .

CANCER CELL, 2002, 1 (05) :421-432

[6]

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model [J].

Murray, LJ ;

Abrams, TJ ;

Long, KR ;

Ngai, TJ ;

Olson, LM ;

Hong, WR ;

Keast, PK ;

Brassard, JA ;

O'Farrell, AM ;

Cherrington, JM ;

Pryer, NK .

CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (08) :757-766

[7]

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model [J].

Ohno, Hiroaki ;

Kubo, Kazuo ;

Murooka, Hideko ;

Kobayashi, Yoshiko ;

Nishitoba, Tsuyoshi ;

Shibuya, Masabumi ;

Yoneda, Toshiyuki ;

Isoe, Toshiyuki .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2634-2643

[8]

Class III receptor tyrosine kinases: Role in leukaemogenesis [J].

Reilly, JT .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (04) :744-757